Okayama University

Nippon Shokubai Co., Ltd.

Momotaro-gene Inc.

Other

Gunma University

Niigata University

Medinet Co., Ltd.

Junichiro Futami

Hidenori Yamada

Hiromi Kumon

Hidetaka Nakanishi

Rie Kinoshita

Masakiyo Sakaguchi

Masami Watanabe

Eisaku Kondo

Ryuji Maekawa

Hiroki Sato

Kazuhiro Kakimi

Midori Kitazoe

Yasuyuki Fujii

Hideo Ueki

Kota Araki

Mikio Okazaki

Kazuhiko Shien

Kazuhiko Ochiai

Masato Shiraki

Shuta Tomida

Shinichi Toyooka

Yusuke Inoue

Go Kyuragi

Akira Yamauchi

Keiichiro Yagi

Takashi Maeda

Provided is a substance capable of effectively suppressing cancer metastasis or a pharmaceutical composition that effectively acts on an inflammatory disease. The pharmaceutical composition is a pharmaceutical composition containing, as an active ingredient, an antibody or an antibody fragment thereof having antigen-binding activity for an S100A8/A9 heterodimer, and blocks interaction between S100A8/A9 and a group of receptors therefor, to thereby strongly suppress cancer metastasis both in vitro and in vivo, or alleviate inflammation. That is, the anti-S100A8/A9 antibody or the antibody fragment thereof can strongly suppress cancer metastasis or alleviate inflammation, by virtue of its blocking action on the interaction between S100A8/A9 and the group of receptors therefor.

Anti-S100A8/A9 antibody and use thereof

The present invention provides the following: a method for efficiently producing a reagent for detecting an antibody that specifically binds with an insoluble antigen protein present in a liquid sample; a reagent for antibody detection produced by the production method; and a use of the antibody. In a step for solubilizing an antigen protein, it is possible to efficiently solubilize and recover the antigen protein by using a cationizing agent; therefore, when compared to conventional methods, it is possible to efficiently produce a reagent for detecting an antibody that has bound to multiple antigen protein molecules in a carrier.

Method for producing reagent for antibody detection and use thereof

This invention provides an anti-REIC antibody that specifically recognizes a cancer-associated protein (REIC/Dkk-3) and enables monitoring of cancer treatment effects involving the use of the REIC/Dkk-3 gene or the REIC/Dkk-3 protein as a medicine. This invention also provides a method of diagnosis involving the use of such antibody. The method of diagnosis comprises a method of cancer detection comprising: measuring the REIC/Dkk-3 protein concentration in the biological sample obtained from a subject with the use of a first antibody or a functional fragment thereof that specifically recognizes the REIC/Dkk-3 protein having an active structure produced by a normal cell but does not recognize and bind to the REIC/Dkk-3 protein existing at a high level in the blood from a cancer patient or has low reactivity with the REIC/Dkk-3 protein existing at a high level in the blood from a cancer patient; and, when the REIC/Dkk-3 protein concentration in the biological sample obtained from the subject is lower than the REIC/Dkk-3 protein concentration in the biological sample from a healthy individual, determining that the subject is suffered from precancer or a neoplastic disease.

Antibody that specifically recognizes and binds to REIC/Dkk-3 protein having active structure and monitoring of cancer treatment using such anti-REIC/Dkk-3 antibody

A polypeptide capable of strongly inducing and activating dendritic-cell-like cells for treating or prevent cancer by immunotherapy, and DNA encoding the polypeptide. The polypeptide is a polypeptide (a) or (b) consisting of a partial region of the REIC/Dkk-3 protein.

Partial region polypeptide of REIC/Dkk-3 protein

The object of the present invention is to provide a novel thiosulfonate compound, a reversible cationization agent for protein and/or peptide, which can reversibly cationize a wider range of proteins and peptides with high stability of quality and accuracy and which are useful for a high degree of purification and recovery, as well as, a method for solubilization for protein and/or peptide using the agent. The present invention is a thiosulfonate compound having three or more cations derived from a quaternary ammonium group within one molecule.

Thiosulfonate compound, reversible cationization agent for protein and/or peptide, and method for solubilization

The invention relates to a method for transducing a pharmaceutical protein or polypeptide that may be fluorescently labeled into a cell by forming a conjugate with a cationic polymer having cation values of more than 2 and no more than 250 and transducing the conjugate into the cell. The protein or peptide pharmaceutical agent is directly covalently bound to the cationic polymer or is covalently bound to the cationic polymer through a bifunctional crosslinking agent.

Method of transducing a protein into cells

A test kit for intracellular introduction of a protein and/or peptide and a method of such intracellular introduction, make it possible for a protein and/or peptide to be introduced into cells efficiently and in an expedient manner while preventing the function of the introduction target protein and/or peptide from being reduced. The above test kit comprises a container containing a cationic group-containing polymer and a container containing a reagent for coupling or binding the cationic group-containing polymer to the protein and/or peptide, or comprises a container containing a cationized conjugate to be coupled to the protein and/or peptide. The above method comprises using a conjugate generated by coupling or binding a cationic group-containing polymer to a protein and/or peptide as a carrier for the introduction target protein and/or peptide.

Test kit for intracellular introduction of protein and/or peptide and method of intracellular introduction

Growing community of inventors

Okayama, Japan

Junichiro Futami